» Authors » Robert Clancy

Robert Clancy

Explore the profile of Robert Clancy including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 48
Citations 1009
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Kaizer A, Lindblade C, Clancy R, Tebo A, Drewes B, Masson M, et al.
Am J Obstet Gynecol . 2022 Jun; 227(5):761.e1-761.e10. PMID: 35690080
Background: The risk of fetal atrioventricular block in anti-Ro/SSA antibody-exposed pregnancies with no previous affected offspring is approximately 2%. A high antibody titer is necessary but not sufficient for atrioventricular...
12.
Fava A, Rao D, Mohan C, Zhang T, Rosenberg A, Fenaroli P, et al.
Arthritis Rheumatol . 2021 Nov; 74(5):829-839. PMID: 34783463
Objective: Current lupus nephritis (LN) treatments are effective in only 30% of patients, emphasizing the need for novel therapeutic strategies. We undertook this study to develop mechanistic hypotheses and explore...
13.
Gomes C, Zuniga M, Crotty K, Qian K, Tovar N, Lin L, et al.
Life Sci Alliance . 2021 Sep; 4(11). PMID: 34504035
High levels of autoimmune antibodies are observed in COVID-19 patients but their specific contribution to disease severity and clinical manifestations remains poorly understood. We performed a retrospective study of 115...
14.
Cornwell M, Luttrell-Williams E, Golpanian M, El Bannoudi H, Myndzar K, Izmirly P, et al.
Lupus Sci Med . 2021 Mar; 8(1). PMID: 33737451
Objective: Hydroxychloroquine (HCQ) is a mainstay of therapy in the treatment of SLE. The effect of HCQ on platelets and vascular health is uncertain. We investigated the relationship between HCQ...
15.
Pudipeddi A, Liu J, Kariyawasam V, Borody T, Cowlishaw J, McDonald C, et al.
Med J Aust . 2021 Jan; 214(8):365-370. PMID: 33502004
Objectives: To determine the age-standardised prevalence of inflammatory bowel disease (IBD) in a metropolitan area of Sydney, with a focus on its prevalence among older people. Design, Setting: Population-based epidemiological...
16.
Friedman D, Kim M, Costedoat-Chalumeau N, Clancy R, Copel J, Phoon C, et al.
Circ Arrhythm Electrophysiol . 2020 Sep; 13(10):e008686. PMID: 32907357
Background: Based on inhibition of viral replication and limited reports on clinical efficacy, hydroxychloroquine is being considered as prophylaxis and treatment of coronavirus disease-19 (COVID-19). Although hydroxychloroquine is generally considered...
17.
Izmirly P, Kim M, Friedman D, Costedoat-Chalumeau N, Clancy R, Copel J, et al.
J Am Coll Cardiol . 2020 Jul; 76(3):292-302. PMID: 32674792
Background: Experimental and clinical evidence support the role of macrophage Toll-like receptor signaling in maternal anti-SSA/Ro-mediated congenital heart block (CHB). Objectives: Hydroxychloroquine (HCQ), an orally administered Toll-like receptor antagonist widely...
18.
Fava A, Buyon J, Mohan C, Zhang T, Belmont H, Izmirly P, et al.
JCI Insight . 2020 May; 5(12). PMID: 32396533
Lupus nephritis, one of the most serious manifestations of systemic lupus erythematosus (SLE), has a heterogeneous clinical and pathological presentation. For example, proliferative nephritis identifies a more aggressive disease class...
19.
Der E, Suryawanshi H, Morozov P, Kustagi M, Goilav B, Ranabothu S, et al.
Nat Immunol . 2019 Oct; 20(11):1556. PMID: 31605099
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
20.
Suryawanshi H, Clancy R, Morozov P, Halushka M, Buyon J, Tuschl T
Cardiovasc Res . 2019 Oct; 116(8):1446-1457. PMID: 31589297
Aims: Investigating human heart development and applying this to deviations resulting in disease is incomplete without molecular characterization of the cell types required for normal functioning. We investigated foetal human...